Silence Therapeutics plc (SLN) Stock Forecast
SLN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.29 / 5 from 7 analysts
- Price target
- $33.00 average of analyst targets
- Upside to target
- +280.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.26
- 52-week range
- $4.30 – $15.43
SLN analyst ratings
7 analystsNumber of analysts at each rating.
SLN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SLN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.09 | −$0.09 | −$0.15 | +40.0% | 1 |
| Current fiscal year (2026) | −$0.36 | −$0.37 | −$0.36 | −$1.85 | +80.2% | 2 |
| Next fiscal year (2027) | −$0.38 | −$0.38 | −$0.38 | −$0.36 | −4.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SLN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $20,670 | $0 | $124,000 | −83.0% | 6 |
| Current fiscal year (2026) | $325,010 | $296,000 | $462,000 | −22.3% | 7 |
| Next fiscal year (2027) | $750,530 | $0 | $4.4M | +130.9% | 7 |
SLN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SLN revenue: reported and forecast
SLN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.18 | −$0.18 | −$0.09 | −10.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.40 | −$0.40 | −$0.72 | −$0.72 | −$0.36 | −8.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.39 | −$0.39 | −$0.77 | −$0.77 | −$0.38 | −2.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SLN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SLN beat in 6 of 12.
What analysts expect from SLN
7 analysts cover Silence Therapeutics; their consensus rating is buy (4.29 on a 1–5 scale, where 5 is a strong buy). The average price target is $33.00, 280.2% above the latest close of $8.68. Analysts expect earnings of −$0.36 per share for 2026, +80.2% from a year earlier. For 2027 the average estimate is −$0.38 per share on revenue of $0.8 million. Silence Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: SLN income statement, SLN key metrics, SLN chart. See the SLN stock overview for the latest quote and news.
SLN forecast FAQ
What is Silence Therapeutics's price target?
The average analyst price target for Silence Therapeutics is $33.00, 280.2% above the latest close of $8.68.
Is Silence Therapeutics a buy, hold or sell?
Of 7 analysts covering Silence Therapeutics, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Silence Therapeutics's EPS forecast?
Analysts forecast −$0.36 per share for 2026 (range −$0.37 to −$0.36); for 2027 the estimate is −$0.38.
What is Silence Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.3 million, growth of −22.3%; for 2027 it is $0.8 million.
When does Silence Therapeutics report earnings?
Silence Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.26.
Does Silence Therapeutics usually beat earnings estimates?
Silence Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.